Improving primary care management of asthma: do we know what really works?
- PMID: 32555169
- PMCID: PMC7300034
- DOI: 10.1038/s41533-020-0184-0
Improving primary care management of asthma: do we know what really works?
Abstract
Asthma imposes a substantial burden on individuals and societies. Patients with asthma need high-quality primary care management; however, evidence suggests the quality of this care can be highly variable. Here we identify and report factors contributing to high-quality management. Twelve primary care global asthma experts, representing nine countries, identified key factors. A literature review (past 10 years) was performed to validate or refute the expert viewpoint. Key driving factors identified were: policy, clinical guidelines, rewards for performance, practice organisation and workforce. Further analysis established the relevant factor components. Review evidence supported the validity of each driver; however, impact on patient outcomes was uncertain. Single interventions (e.g. healthcare practitioner education) showed little effect; interventions driven by national policy (e.g. incentive schemes and teamworking) were more effective. The panel's opinion, supported by literature review, concluded that multiple primary care interventions offer greater benefit than any single intervention in asthma management.
Conflict of interest statement
D.L. is an employee of GlaxoSmithKline plc., and holds stocks in GlaxoSmithKline plc. M.F. and T.v.d.M. are former employees of GlaxoSmithKline plc., and M.F. holds stocks in GlaxoSmithKline plc. I.T. reports advisory boards from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline plc. and Novartis and a grant from GlaxoSmithKline Greece, outside the submitted work. J.K. reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants from Chiesi, grants and personal fees from GlaxoSmithKline plc., grants and personal fees from Novartis, grants from Mundipharma, grants from TEVA, outside the submitted work. A.C. reports a grant from AstraZeneca for an asthma study. C.C. reports grants from Pfizer China, outside of the submitted work. M.T. reports the following conflicts of interest: neither M.T. nor any member of his close family has any shares in pharmaceutical companies; receipt in the last 3 years of speaker’s honoraria for speaking at sponsored meetings or satellite symposia at conferences from GlaxoSmithKline plc. and Novartis, companies marketing respiratory and allergy products; receipt of honoraria for attending advisory panels with Boehringer Inglehiem, GlaxoSmithKline plc. and Novartis; membership of the BTS SIGN Asthma guideline steering group and the NICE Asthma Diagnosis and Monitoring guideline development group. P.K. reports personal fees from AstraZeneca, GlaxoSmithKline plc., Chiesi, Menarini, Novartis, Klosterfrau, Bionorica, Willmar Schwabe and MSD, and other support (for a phase 3 investigator cough study) from MSD, all outside the submitted work. C.S. has no shares in any pharmaceutical companies, she has received consultant agreements and honoraria for presentations from several pharmaceutical companies that market inhaled medication including AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline plc., Napp Pharmaceuticals and Teva. J.C.d.S. reports personal fees and speaker’s honoraria from Boheringer Ingelheim, personal fees and speaker’s honoraria from GlaxoSmithKline plc., personal fees and speaker’s honoraria from AstraZeneca, personal fees and speaker’s honoraria from Mundipharma outside the submitted work. M.R.R. reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline plc., personal fees from Menarini, personal fees from Mundipharma, personal fees from Novartis, personal fees from Pfizer, personal fees from Teva, personal fees from Bial, outside the submitted work. E.M.K. received honoraria for attending advisory board meeting from GlaxoSmithKline plc., Boehringer Inglehiem and grant from Novartis outside the submitted work.
Figures

Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Evaluation of a practice-based intervention to improve the management of pediatric asthma.J Urban Health. 2011 Feb;88 Suppl 1(Suppl 1):38-48. doi: 10.1007/s11524-010-9471-3. J Urban Health. 2011. PMID: 21337050 Free PMC article.
-
Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program.MMWR Recomm Rep. 2003 Mar 28;52(RR-6):1-8. MMWR Recomm Rep. 2003. PMID: 12696781
-
Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.Health Technol Assess. 2020 Sep;24(46):1-490. doi: 10.3310/hta24460. Health Technol Assess. 2020. PMID: 32975190 Free PMC article.
-
Adult patient access to electronic health records.Cochrane Database Syst Rev. 2021 Feb 26;2(2):CD012707. doi: 10.1002/14651858.CD012707.pub2. Cochrane Database Syst Rev. 2021. PMID: 33634854 Free PMC article.
Cited by
-
Exploring the Relationship between Wind Patterns and Hospital Admissions Due to Respiratory Symptoms in Children.Children (Basel). 2024 Jun 12;11(6):717. doi: 10.3390/children11060717. Children (Basel). 2024. PMID: 38929296 Free PMC article.
-
Integrating asthma care guidelines into primary care electronic medical records: a review focused on Canadian knowledge translation tools.Eur Respir Rev. 2024 Nov 27;33(174):230247. doi: 10.1183/16000617.0247-2023. Print 2024 Oct. Eur Respir Rev. 2024. PMID: 39603664 Free PMC article. Review.
-
Evaluation of a Primary Care-Integrated Mobile Health Intervention to Monitor between-Visit Asthma Symptoms.Appl Clin Inform. 2024 Aug;15(4):785-797. doi: 10.1055/s-0044-1788978. Epub 2024 Oct 2. Appl Clin Inform. 2024. PMID: 39357877 Clinical Trial.
-
User-centered design of a scalable, electronic health record-integrated remote symptom monitoring intervention for patients with asthma and providers in primary care.J Am Med Inform Assoc. 2021 Oct 12;28(11):2433-2444. doi: 10.1093/jamia/ocab157. J Am Med Inform Assoc. 2021. PMID: 34406413 Free PMC article.
-
The Impact of the Quality of Care for Adults with Acute Asthma in the Emergency Department of a Tertiary Hospital: A 1-Year Follow-Up Study.Clin Pract. 2025 Jun 24;15(7):116. doi: 10.3390/clinpract15070116. Clin Pract. 2025. PMID: 40710026 Free PMC article.
References
-
- Global Asthma Network. The Global Asthma Report 2018. http://www.globalasthmanetwork.org/Global%20Asthma%20Report%202018.pdf (2018).
-
- Global Initiative for Asthma. Global strategy for asthma management and prevention. www.ginasthma.com (2019).
-
- Royal College of Physicians. Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry Report (Royal College of Physicians, London, 2014).
-
- Kirenga BJ, et al. Rates of asthma exacerbations and mortality and associated factors in Uganda: a 2-year prospective cohort study. Thorax. 2018;73:983–985. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous